Novellus

Novellus is a clinical-stage biotechnology company focused on the development of compounds for established oncogene drivers with a high incidence of uncharacterized mutations.

Novellus develops highly selective medicines for functionally and genomically defined cancer patients.

Novellus was founded in 2011 and is headquartered in Jerusalem, Israel.

Novellus' landmark technology is expected to shorten the diagnostic process, reduce unnecessary medical procedures, and lead to significant cost savings.

NovellusDx is able to characterize the activity of unknown mutations in cancer patients, and test their response to targeted therapies. Its industry-leading FACT platform recapitulates naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds.

 

NovellusDx collaborates with large Pharma, biotech and diagnostic companies, as well as, with leading medical centers, such as MD Anderson, Memorial Sloan-Kettering and others.

 

Novellus is backed by OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Pontifax, Cormorant Asset Management, Novartis Venture Fund (NVF), SR One and others. The company raised $57M in Series C round on Sep 21, 2020. This brings Novellus' total funding to $91.5M to date.

 

 

  • Year founded: 2011
  • Funding Info: $91.5M over 5 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Jerusalem
  • State: Jerusalem
  • Country: Israel
Related businesses